Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin.

Demehri S, Turkoz A, Manivasagam S, Yockey LJ, Turkoz M, Kopan R.

Cancer Cell. 2012 Oct 16;22(4):494-505. doi: 10.1016/j.ccr.2012.08.017.

2.

Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting.

Di Piazza M, Nowell CS, Koch U, Durham AD, Radtke F.

Cancer Cell. 2012 Oct 16;22(4):479-93. doi: 10.1016/j.ccr.2012.08.016.

3.

Cancer classification using the Immunoscore: a worldwide task force.

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

J Transl Med. 2012 Oct 3;10:205. doi: 10.1186/1479-5876-10-205. Review.

4.

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS.

Nat Med. 2012 Sep;18(9):1359-68.

5.

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.

Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J, Novik Y, Tiersten A, Goldberg JD, Formenti SC, Bhardwaj N, Unutmaz D, Demaria S.

Clin Cancer Res. 2012 Dec 15;18(24):6748-57. doi: 10.1158/1078-0432.CCR-12-1149. Epub 2012 Jul 5.

6.

Th17 cells have stem cell-like features and promote long-term immunity.

Wei S, Zhao E, Kryczek I, Zou W.

Oncoimmunology. 2012 Jul 1;1(4):516-519.

7.

Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.

Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D.

Cancer Cell. 2012 Jun 12;21(6):836-47. doi: 10.1016/j.ccr.2012.04.024.

8.

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH.

Cancer Cell. 2012 Jun 12;21(6):822-35. doi: 10.1016/j.ccr.2012.04.025.

9.

Accessories to the crime: functions of cells recruited to the tumor microenvironment.

Hanahan D, Coussens LM.

Cancer Cell. 2012 Mar 20;21(3):309-22. doi: 10.1016/j.ccr.2012.02.022. Review.

10.

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.

Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD.

Nature. 2012 Feb 8;482(7385):400-4. doi: 10.1038/nature10755.

11.

Differential macrophage programming in the tumor microenvironment.

Ruffell B, Affara NI, Coussens LM.

Trends Immunol. 2012 Mar;33(3):119-26. doi: 10.1016/j.it.2011.12.001. Epub 2012 Jan 23. Review.

12.

The immune score as a new possible approach for the classification of cancer.

Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA.

J Transl Med. 2012 Jan 3;10:1. doi: 10.1186/1479-5876-10-1.

13.

Cancer-related inflammation: common themes and therapeutic opportunities.

Balkwill FR, Mantovani A.

Semin Cancer Biol. 2012 Feb;22(1):33-40. doi: 10.1016/j.semcancer.2011.12.005. Epub 2011 Dec 24. Review.

PMID:
22210179
14.

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.

Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA.

Genes Dev. 2011 Dec 1;25(23):2465-79. doi: 10.1101/gad.180331.111.

15.

B cells and autoimmunity.

Pillai S, Mattoo H, Cariappa A.

Curr Opin Immunol. 2011 Dec;23(6):721-31. doi: 10.1016/j.coi.2011.10.007. Epub 2011 Nov 24. Review.

16.

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM.

Cancer Discov. 2011 Jun;1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028. Epub 2011 Jun 1.

17.

Therapeutic intervention in cancer and chronic viral infections: antibody mediated manipulation of PD-1/PD-L1 interaction.

Sakthivel P, Gereke M, Bruder D.

Rev Recent Clin Trials. 2012 Feb;7(1):10-23. Review.

PMID:
22023178
18.

Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

Horikawa M, Minard-Colin V, Matsushita T, Tedder TF.

J Clin Invest. 2011 Nov;121(11):4268-80. doi: 10.1172/JCI59266. Epub 2011 Oct 24.

19.

Extracellular matrix degradation and remodeling in development and disease.

Lu P, Takai K, Weaver VM, Werb Z.

Cold Spring Harb Perspect Biol. 2011 Dec 1;3(12). pii: a005058. doi: 10.1101/cshperspect.a005058. Review.

20.

Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling.

Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2802-7. doi: 10.1073/pnas.1108781108. Epub 2011 Sep 9.

Supplemental Content

Support Center